Variable | HR (95% CI) | p |
Grouped Stages | ||
Early | Reference |
|
Advanced | 2.03 (1.45 - 2.84) | 0.000 |
Metastatic | 1.47 (0.83 - 2.58) | 0.186 |
Age grouped | ||
<46 years | Reference |
|
46 - 54 | 0.76 (0.48 - 1.22) | 0.253 |
55 - 64 | 1.02 (0.65 - 1.59) | 0.946 |
≥65 years | 1.54 (1.02 - 2.32) | 0.039 |
Localization | ||
UOQ | Reference |
|
LOQ | 1.10 (0.67 - 1.81) | 0.707 |
UIQ | 1.12 (0.74 - 1.70) | 0.590 |
UIQ | 0.80 (0.42 - 1.51) | 0.494 |
Retro areolar | 0.61 (0.34 - 1.10) | 0.099 |
Multifocal | 2.88 (1.52 - 5.45) | 0.001 |
Multicentric | 1.23 (0.82 - 1.85) | 0.322 |
Differentiation | ||
Well | Reference |
|
Moderately | 2.21 (1.33 - 3.65) | 0.002 |
Poorly | 2.57 (1.53 - 4.33) | 0.000 |
Phenotype | ||
Luminal A | Reference |
|
Luminal B | 1.26 (0.73 - 2.19) | 0.408 |
HER2 positive | 1.07 (0.66 - 1.73) | 0.797 |
Triple negative | 1.72 (1.18 - 2.53) | 0.005 |
Type of surgery | ||
No surgery | Reference |
|
Conservative | 0.48 (0.29 - 0.78) | 0.003 |
Radical | 0.52 (0.35 - 0.79) | 0.002 |
Metastatic disease | ||
NO metastasis | Reference |
|
Metastasis | 4.91 (3.62 - 6.65) | 0.000 |